InvestorsHub Logo
Followers 0
Posts 798
Boards Moderated 0
Alias Born 07/27/2018

Re: None

Sunday, 03/10/2019 2:38:59 PM

Sunday, March 10, 2019 2:38:59 PM

Post# of 41240
Ok maybe its a bad Idea to sprinkle RS protection on your bio tech shares. Because then the company goes belly up from lack of funding. But that suggests the expenses of developing in biotech is financially unreasonable. We hit a capitalist road block in technological progression where the financial risk outweighs the reward and go into screwy finance to make it feasible. So we need subsidizing like corn like space tech like Nasa. But then this bounces back to what Ive been talking about DOE and Berkeley national lab and national labs in general here and in biotech in general.

lloyd doggett is suggesting he address something that looks like FDA has already addressed with device tracking and new fda clearance techniques. I think there's a journalistic story here that starts with metallosis goes into the problem of how novel biotech financially attempt to stay alive and the problem with that and national lab IP then ends with addressing the need to financially subsidize development like corn to create a healthy state of biotech development to encourage it and remove the road block and foster innovation. That's essentially what the new clearance paths in the FDA attempt to do. Foster innovation.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News